Hall of Fame Resort & Entertainment Company Announces Closing of $25.0 Million Underwritten Public Offering

Hall of Fame Resort & Entertainment Company Announces Closing of $25.0 Million Underwritten Public Offering

CANTON, Ohio–(BUSINESS WIRE)–
Hall of Fame Resort & Entertainment Company (“HOFV” or the “Company”) (NASDAQ: HOFV, HOFVW), the only resort, entertainment and media company centered around the power of professional football and owner of the Hall of Fame Village powered by Johnson Controls, today announced the closing of its previously announced public offering of 17,857,142 units at a price of $1.40 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. In addition, the Company had granted to Maxim Group LLC a 45-day option to purchase up to an additional 2,678,571 shares of common stock and/or warrants to purchase up to 2,678,571 shares of common stock at the public offering price less discounts and commissions, of which Maxim Group LLC has exercised its option to purchase warrants to purchase up to 2,678,571 shares of common stock. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are approximately $25.0 million.

The warrants are immediately exercisable at a price of $1.40 per share of common stock and expire five years from the date of issuance. The shares of common stock and the accompanying warrants were purchased together in the offering, but were issued separately.

Maxim Group LLC acted as sole book-running manager for the offering. The offering was conducted pursuant to the Company’s registration statement on Form S-1 (File No. 333- 249133), as amended, and the Company’s registration statements on Form S-1 (File Nos. 333-250119 and 333-250119), previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A final prospectus relating to the offering has been be filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Electronic copies of the prospectus relating to this offering may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About the Hall of Fame Resort & Entertainment Company

The Hall of Fame Resort & Entertainment Company (NASDAQ: HOFV, HOFVW) is a resort and entertainment company leveraging the power and popularity of professional football and its legendary players in partnership with the Pro Football Hall of Fame. Headquartered in Canton, Ohio, the Hall of Fame Resort & Entertainment Company is the owner of the Hall of Fame Village powered by Johnson Controls, a multi-use sports, entertainment and media destination centered around the Pro Football Hall of Fame’s campus. Additional information on the Company can be found at www.HOFREco.com.

Forward-Looking Statements Disclaimer Statement

This communication contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 about us that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “going to,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “propose”, “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements in this communication include, but are not limited to, statements about: the benefits of the business combination; the future financial performance of the Company‘s following the business combination; changes in the market in which the Company competes; expansion and other plans and opportunities; the effect of the COVID-19 pandemic on the Company’s business; the Company’s ability to raise financing in the future; the possibility of sports betting becoming legal in Ohio; and the Company‘s ability to maintain the listing of its common stock on Nasdaq following the business combination. These statements are based on the current expectations of the Company’s management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties and the Company’s business and actual results may differ materially. These risks and uncertainties include, but are not limited to the inability to recognize the anticipated benefits of the business combination; costs related to the business combination; the Company’s ability to manage growth; the Company’s ability to execute its business plan and meet its projections; potential litigation involving the Company; changes in applicable laws or regulations; the potential adverse effect of the COVID-19 pandemic on capital markets, general economic conditions, unemployment and the Company’s liquidity, operations and personnel. Additional information and “Risk Factors” are available in other filings that we make from time to time with the SEC, included in the Registration Statement. In addition, the forward-looking statements in this communication relate only to events as of the date on which the statements are made and are based on information available to us as of the date of this communication. We undertake no obligation to update any forward-looking statements made in this communication to reflect events or circumstances after the date of this communication.

Media/Investor Contacts:

For Hall of Fame Resort & Entertainment Company

Media Inquiries: [email protected]

Investor Inquiries: [email protected]

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Other Sports Sports General Sports Entertainment Football Other Entertainment General Entertainment Lodging Destinations Travel

MEDIA:

Logo
Logo

Saint Jean Carbon Announces Loan Bonus, Share for Debt Transaction and Provides an Update on the Offtake Agreement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

OAKVILLE, Ontario, Nov. 18, 2020 (GLOBE NEWSWIRE) — Saint Jean Carbon Inc. (“SaintJean” or the “Company”) (TSX-V: SJL) is pleased to announce that, subject to the approval by the TSX Venture Exchange (the “Exchange”), the Company has agreed to issue, pursuant to Policy 5.1 of the Exchange, a loan bonus to two (2) arm’s length third party lenders (the “Lenders”) of 115,000 common shares in the capital of the Company in the aggregate (the “Bonus Shares”) at a deemed price of $0.05 per Bonus Share, pursuant to terms of the loans previously obtained by the Company from the Lenders. The Company had previously obtained loans from the Lenders in the aggregate amount of $40,000 (collectively the “Loans”). The lenders were Gilles Ayotte and Bernice Cooper. The Loans bore interest at a rate of twelve percent (12%) per annum and were payable on demand. As the ability of the Company to repay the Loans was not evident at the time of the Loans were advanced, the Company and the Lenders agreed that in consideration of the risks taken by the Lenders, the Company would issue the Bonus Shares to the Lenders. The Company repaid the Loans and accrued interest in full to the Lenders on October 22, 2020 and October 29, 2020, respectively. The Bonus Shares are subject to a four month and one (1) day hold period.


Shares for Debt

The Company also wishes to announce, subject to the approval by the Exchange, that it has agreed to settle an aggregate of $150,000 of debt (the “Debt”) owed to an arm’s length third party service provider by issuing an aggregate of 3,000,000 common shares (the “Shares”) in the capital of the Company at a deemed price of $0.05 per Share (the “Shares for Debt Transaction”). In order to preserve cash for continuing operations, the Company is of the view that it is in its best interests to satisfy the Debt with Shares. The Shares are subject to a four month and one (1) day hold period.


Offtake Agreement

The Company also wishes to elaborate on its arm’s length offtake agreement with Ameca Ltd. (“Ameca”), previously announced on September 30, 2020. A revised agreement was signed on November 5, 2020. Production in Sri Lanka may begin as early as the summer of 2021. Saint Jean intends to pre-sell at least 10,000 tonnes of the highest quality graphite in the world, verified in Saint Jean’s R&D facility, to a third party and never take physical possession of the material. Ameca and Saint Jean have agreed on a formula of profit sharing on all sales. The intent is to sell the entire 15,000 tonnes of graphite under the Company’s offtake agreement with Ameca. Ameca’s planned initial production is 15,000 tonnes per year.

About Saint Jean

Saint Jean is a publicly traded carbon science company, with specific interests in energy storage and green energy creation and green re-creation, with holdings in mining claims in the province of British Columbia in Canada. For the latest information on Saint Jean’s properties and news please refer to the website: http://www.saintjeancarbon.com/

On behalf of the Board of Directors
Saint Jean Carbon Inc.
William Pfaffenberger, Chairman of the Board, President and Intérim CFO

Information Contact:

Email: [email protected]
Tel: (250) 381-6181

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


FORWARD LOOKING STATEMENTS:

This press release contains forward-looking statements, within the meaning of applicable securities legislation, concerning Saint Jean’s business and affairs.  In certain cases, forward-looking statements can be identified by the use of words such as ‘‘plans’’, ‘‘expects’’ or ‘‘does not expect’’, “intends” ‘‘budget’’, ‘‘scheduled’’, ‘‘estimates’’, “forecasts’’, ‘‘intends’’, ‘‘anticipates’’ or variations of such words and phrases or state that certain actions, events or results ‘‘may’’, ‘‘could’’, ‘‘would’’, ‘‘might’’ or ‘‘will be taken’’, ‘‘occur’’ or ‘‘be achieved’’.   Such forward-looking statements include those with respect to: (
i
) the approval by the Exchange of the Bonus Shares; (ii) the issuance of the Bonus Shares; (iii) completion of the Shares for Debt Transaction; (iv) the approval by the Exchange of the Shares for Debt Transaction; (v) the expected commencement of production in Sri Lanka; (vi) the intention to pre-sell at least 10,000 tonnes of graphite in the world; and (vii)
the
intention to sell 15,000 tonnes of graphite to
Ameca
. These forward-looking statements are based on current expectations, and are naturally subject to uncertainty and changes in circumstances that may cause actual results to differ materially.  Although Saint Jean believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that these expectations will prove to be correct.

Statements of past performance should not be construed as an indication of future performance. Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors, including those discussed above, could cause actual results to differ materially from the results discussed in the forward-looking statements. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement.

All of the forward-looking statements made in this press release are qualified by these cautionary statements.  Readers are cautioned not to place undue reliance on such forward-looking statements.  Forward-looking information is provided as of the date of this press release, and Saint Jean assumes no obligation to update or revise them to reflect new events or circumstances, except as may be required under applicable securities legislation.



Consonance-HFW Acquisition Corp. Announces Pricing of Its Initial Public Offering

Consonance-HFW Acquisition Corp. Announces Pricing of Its Initial Public Offering

NEW YORK–(BUSINESS WIRE)–
Consonance-HFW Acquisition Corp. (“Consonance-HFW”) announced today the pricing of its initial public offering of 8,000,000 units, at a price to the public of $10.00 per unit, for aggregate gross proceeds of $80,000,000. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share. The units are expected to begin trading on the New York Stock Exchange on November 19, 2020 under the symbol “CHFW.U”. The offering is expected to close on November 23, 2020, subject to customary closing conditions.

Consonance-HFW is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to as our initial business combination. While Consonance-HFW may acquire a company in any industry, it expects that its focus will be on the healthcare industry, particularly the biotechnology sector, in developed countries including, but not limited to, the United States and countries in Europe.

J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Consonance-HFW has granted the underwriter a 45-day option to purchase up to an additional 1,200,000 units at the initial offering price to cover over-allotments, if any.

The offering of these securities is being made only by means of a prospectus. Copies of the prospectus relating to this offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (866) 803-9204 or by email at [email protected].

A registration statement relating to the sale of these securities was filed with, and declared effective by, the Securities and Exchange Commission. Copies of the registration statement can be accessed through the Securities and Exchange Commission’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to Consonance-HFW’s offering and search for an initial business combination. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous risks and conditions, many of which are beyond the control of Consonance-HFW, including those set forth in the Risk Factors section of Consonance-HFW’s registration statement relating to the offering. Consonance-HFW undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Joshua House

Consonance-HFW Acquisition Corp.

[email protected]

KEYWORDS: Caribbean United States Cayman Islands North America New York

INDUSTRY KEYWORDS: Biotechnology Health Professional Services Other Professional Services Small Business

MEDIA:

Logo
Logo

Group 1 Automotive to Present at Stephens Annual Investment Conference 2020

PR Newswire

HOUSTON, Nov. 18, 2020 /PRNewswire/ — Group 1 Automotive, Inc. (NYSE: GPI), (“Group 1” or the “Company”), an international, Fortune 500 automotive retailer, today announced that senior management will present at the Stephens Annual Investment Conference 2020 on Thursday, November 19, 2020.  The virtual conference presentation is scheduled to begin at 3:00 p.m. E.T.

A softcopy of the Company’s presentation material provided at the virtual conference will also be available within http://www.group1corp.com/events and within the Investor Relations section of Group 1’s website at http://group1corp.com/company-presentations


About Group 1 Automotive, Inc.


Group 1 owns and operates 185 automotive dealerships, 241 franchises, and 49 collision centers in the United States, the United Kingdom and Brazil that offer 31 brands of automobiles. Through its dealerships, the Company sells new and used cars and light trucks; arranges related vehicle financing; sells service contracts; provides automotive maintenance and repair services; and sells vehicle parts.

Investors please visit www.group1corp.com, www.group1auto.com, www.group1collision.com, www.facebook.com/group1auto, and www.twitter.com/group1auto, where Group 1 discloses additional information about the Company, its business, and its results of operations.

Investor contacts:

Sheila Roth

Manager, Investor Relations
Group 1 Automotive, Inc.
713-647-5741 | [email protected]

Media contacts:

Pete DeLongchamps

Senior V.P. Manufacturer Relations, Financial Services and Public Affairs
Group 1 Automotive, Inc.
713-647-5770 | [email protected]
or
Clint Woods
Pierpont Communications, Inc.
713-627-2223 | [email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/group-1-automotive-to-present-at-stephens-annual-investment-conference-2020-301176541.html

SOURCE Group 1 Automotive, Inc.

Quest Diagnostics Declares Quarterly Cash Dividend

PR Newswire

SECAUCUS, N.J., Nov. 18, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.56 per share, payable on February 3, 2021 to shareholders of record of Quest Diagnostics common stock on January 20, 2021.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-declares-quarterly-cash-dividend-301176537.html

SOURCE Quest Diagnostics

Owens & Minor Prepares for Flu Season with Increased Made-in-Americas Mask and N95 Respirator Capacity

Owens & Minor Prepares for Flu Season with Increased Made-in-Americas Mask and N95 Respirator Capacity

For the past 20 years, global healthcare manufacturer’s HALYARD-branded product line of masks and N95 respirators has ranked at the top of the facial protection market

RICHMOND, Va.–(BUSINESS WIRE)–
As the United States prepares to enter flu season under the persistent COVID-19 pandemic, Owens & Minor (NYSE: OMI), the nation’s leading producer of medical-grade facial protection products, continues to increase production and invest in its capacity to provide frontline workers with procedure masks and N95 respirators.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118006135/en/

Owens & Minor's HALYARD-branded Surgical N95 Respirators are made to protect frontline workers from airborne illnesses, which is why the form, fit and comfort are of utmost importance. (Photo: Business Wire)

Owens & Minor’s HALYARD-branded Surgical N95 Respirators are made to protect frontline workers from airborne illnesses, which is why the form, fit and comfort are of utmost importance. (Photo: Business Wire)

“At the onset of the COVID-19 pandemic, Owens & Minor acted with urgency and investment to deliver an increased supply of facial protection products, including procedure masks and N95 respirators,” said Edward A. Pesicka, President and CEO of Owens & Minor. “We are laser-focused on providing the highest quality products that are specifically designed for medical staff and essential workers. Frontline workers need protection now, and we are working tirelessly to meet that need.”

Since February, Owens & Minor has acted across four key categories and is poised to help support the nation’s critical facial protection needs:

  • Surgical N95 Respirators: Over 1000% increase in N95 production at three Americas locations, including additional manufacturing assets in Del Rio, Texas and Lexington, N.C.
  • Surgical and Procedure Masks: Nearly 100% increase in surgical and procedure mask production through new capital investment and improving efficiency of operations in Acuña, Mexico
  • Face Shields: Over 600% increase in face shields through new capital investment in Acuña, Mexico
  • Raw Materials: Additional, dedicated meltblown fabric manufacturing line in Lexington, N.C. to ensure end-to-end control of Owens & Minor supply chain, providing self-sufficiency from base material to finished mask—unlike other suppliers who rely on supply from Asia

The significant improvements across Owens & Minor’s facial protection categories were made possible by capital investments, improved rates of operation and increased production capacity to 24/7 shifts.

“Unlike many other manufacturers of facial protection products, Owens & Minor has more than a century of healthcare experience and is proud of our Americas-based manufacturing of medical-grade N95s dating to 1997,” said Pesicka. “We stand ready to provide protection for healthcare workers on the frontlines battling flu and COVID-19. Our Surgical N95 Respirators are made to protect frontline workers from airborne illnesses, which is why the form, fit and comfort of our respirators are of paramount importance.”

Owens & Minor’s HALYARD* FLUIDSHIELD* Surgical N95 Respirators are:

  • 100% Medical Grade: While the FDA has granted temporary emergency use authorization for some industrial grade N95s, HALYARD* FLUIDSHIELD* Surgical N95 Respirators are designed and manufactured in accordance with our own FDA cleared 510(k).
  • Made in the Americas, from Base Material to Finished Respirator: Unlike suppliers who rely on sources from Asia, all HALYARD* FLUIDSHIELD* Surgical N95s are manufactured in the Americas.
  • Highest Level of Protection: All HALYARD* FLUIDSHIELD* Respirators deliver Level 3 splash and spray protection—the highest recognized level of protection.
  • Specially Designed for Medical Staff and Essential Workers: The duckbill breathing chamber is more than twice as large as the leading surgical N95 respirator and exceeds NIOSH standards for breathability. Because proper snug fit is critical, HALYARD-brand N95s come in a range of sizes, with malleable nose wire to adjust fit. They have strong elastic straps that are securely bonded—not stapled—to the mask.
  • Reliably Supplied Every Day: With manufacturing investment and end-to-end control of its entire supply chain, Owens & Minor has been able to ramp up N95 production to consistently exceed customer historical usage levels even during the pandemic.

Owens & Minor proactively engages with AAMI, NIOSH and ASTM guideline panels to keep abreast of evolving standards and ensure the best protection provided by its products. The company holds over 30 patents in facial protection innovation.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a global healthcare solutions company with integrated technologies, products, and services aligned to deliver significant and sustained value for healthcare providers and manufacturers across the continuum of care. With over 15,000 dedicated teammates serving healthcare industry customers in 70 countries, Owens & Minor helps to reduce total costs across the supply chain by optimizing episode and point-of-care performance, freeing up capital and clinical resources, and managing contracts to optimize financial performance. A FORTUNE 500 company, Owens & Minor was founded in 1882 in Richmond, Virginia, where it remains headquartered today. The Company has distribution, production, customer service and sales facilities located across the Asia Pacific region, Europe, Latin America, and North America. For more information about Owens & Minor, visit owens-minor.com, follow @Owens_Minor on Twitter, and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.

Jayme Maniatis

781-684-6610

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Medical Supplies Health Medical Devices Infectious Diseases Hospitals Other Health General Health

MEDIA:

Logo
Logo
Photo
Photo
Owens & Minor’s HALYARD-branded Surgical N95 Respirators are made to protect frontline workers from airborne illnesses, which is why the form, fit and comfort are of utmost importance. (Photo: Business Wire)

Sanderson Farms Announces Webcast Replay for Stephens Investment Conference

Sanderson Farms Announces Webcast Replay for Stephens Investment Conference

LAUREL, Miss.–(BUSINESS WIRE)–
Sanderson Farms, Inc. (NASDAQ: SAFM) made a virtual investor presentation today as a participant in the Stephens Annual Investment Conference. The link to the webcast that was originally posted to the Company’s website was incorrect and did not allow access to the live event for a portion of the presentation.

A replay of the entire investor presentation by Joe F. Sanderson, Jr., chairman and chief executive officer, and Mike Cockrell, treasurer, chief financial officer and chief legal officer, will be available by close of business on Friday, November 20, 2020. The link to the replay will be found at the investor relations section of the Company’s website, www.sandersonfarms.com, and will be available for a period of one year.

Sanderson Farms, Inc. is engaged in the production, processing, marketing and distribution of fresh, frozen and minimally prepared chicken. Its shares trade on the NASDAQ Global Select Market under the symbol SAFM.

Mike Cockrell

Treasurer, Chief Financial Officer &

Chief Legal Officer

(601) 649-4030

KEYWORDS: Mississippi United States North America

INDUSTRY KEYWORDS: Retail Agriculture Natural Resources Food/Beverage

MEDIA:

Logo
Logo

NCLA Keeps Fighting Against Gov. Murphy’s Unlawful Effort to Rewrite Every Residential Lease in NJ

Matthew Johnson, et al. v. Governor Philip D. Murphy, et al.

Washington, D.C., Nov. 18, 2020 (GLOBE NEWSWIRE) — The New Civil Liberties Alliance, a nonpartisan, nonprofit civil rights group, today filed a response to the State’s motion to dismiss in the U.S. District Court for the District of New Jersey in the case of Matthew Johnson, et al. v. Governor Philip D. Murphy, et al. The lawsuit challenges Executive Order No. 128 (EO 128), which violates the Contracts Clause of the U.S. Constitution, as well as New Jersey’s Constitution and statutory laws, by interfering with freely negotiated contracts between tenants and housing providers.

NCLA clients like Mr. Johnson, who owns a small rental property in Cherry Hill, New Jersey, are property owners who rent out their homes to make a living. Most of them own only a single rental unit. The governor’s unconstitutional order victimizes them by allowing tenants to apply their security deposits to cover rent or back rent. The problem is that once a tenant uses up the security deposit in this way, that tenant no longer has a financial incentive to keep the property nice during the remainder of the tenancy, and it leaves the housing provider without any security against damage by the tenant.

Without statutory authority to do so, Governor Murphy purported to rewrite every residential lease in the State of New Jersey unilaterally. On its face EO 128 claims to waive numerous state laws governing security deposits that were adopted by proper, constitutional legislative process. Targeting a single group (i.e., residential tenants) for relief in this manner undermines freedom of contract, due process, and equal protection of the laws. It also ignores the governor’s limited role and disregards the separation of powers among branches of government.

The state’s move to dismiss the complaint for failure to state a claim is a feeble attempt to convince the court that the Contracts Clause, which prohibits states from adopting laws that interfere with contractual obligations, is a dead letter. New Jersey contends that once a state regulates an industry, it can then retroactively nullify any contractual provisions in that sector. Regulated businesses, even individuals who only rent out a single unit, the State argues, have no legitimate expectation against government intervention in their private contracts. 

NCLA’s response refutes the State’s absurd argument. EO 128 rewrites the terms of NCLA’s clients’ contracts, impairs the housing providers’ rights, and far exceeds any limited and temporary contractual interference that the Constitution might tolerate. EO 128 is precisely the type of state action the Framers designed the Contracts Clause to prohibit and is the kind that the Supreme Court has historically struck down. The security deposits for which the Plaintiffs contracted created an incentive for the tenants to comply with the terms of their leases and to maintain the condition of the housing providers’ properties. EO 128 created “every incentive” for the tenants to apply their deposit toward their rent and eliminate the security for which NCLA’s clients had contracted.

NCLA is asking the court to deny the State’s motion to dismiss and allow these New Jersey housing providers to continue pursuing their claims for declaratory and injunctive relief against Gov. Murphy.

NCLA released the following statements:

“It’s clear from the State’s motion to dismiss that Governor Murphy would like nothing more than to avoid judicial scrutiny of his unlawful executive order. And with good reason. EO 128 is a direct affront to the federal Contracts Clause, which exists to invalidate this sort of state interference with private contracts.”

Jared McClain, Litigation Counsel, NCLA

“With one stroke of his pen, Governor Murphy single-handedly rewrote not only our clients’ lease agreements, but every existing residential lease in New Jersey. Governors are not dictators. He does not have the power to do this, and the U.S. Constitution specifically forbids him from doing this. Our clients are simply asking that their private contracts be respected and restored.”

Kara Rollins, Litigation Counsel, NCLA

For more information visit case summary page
here
.

ABOUT NCLA

NCLA is a nonpartisan, nonprofit civil rights group founded by prominent legal scholar Philip Hamburger to protect constitutional freedoms from violations by the Administrative State. NCLA’s public-interest litigation and other pro bono advocacy strive to tame the unlawful power of state and federal agencies and to foster a new civil liberties movement that will help restore Americans’ fundamental rights.

 

 

 

###



Judy Pino, Communications Director
New Civil Liberties Alliance
202-869-5218
[email protected]

Immutep Announces Expansion of TACTI-002 Collaboration Trial

  • Additional 74 patients with 1st line non-small cell lung cancer (NSCLC) to be enrolled, more than tripling patient numbers in this indication
  • Follows encouraging interim data from 1st line NSCLC patients
  • First Patient is expected to be enrolled in the expanded trial by the end of 2020
  • Separately, Immutep has initiated planning for a new randomized, controlled Phase II trial in 1st line Head and Neck Squamous Cell Carcinoma (HNSCC) advancing efti into late stage clinical trials in this indication

SYDNEY, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces it is advancing clinical development for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) through the expansion of its ongoing TACTI-002 study and a new Phase II trial.

TACTI-002 Expansion with Merck & Co, Inc., Kenilworth, NJ, USA

Immutep has expanded its collaboration trial with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada) to include an additional 74 patients with 1st line NSCLC (Part A), the most advanced part of its ongoing Phase II TACTI-002 clinical trial evaluating efti with MSD’s KEYTRUDA® (pembrolizumab, an anti PD-1 treatment). The expansion extends Immutep’s existing clinical trial collaboration and supply agreement with MSD (announced on 12 March 2018).

Additional clinical sites will be added to the existing 12 study centres across Australia, Europe, and the US and the first patient is expected to be enrolled in the expanded trial by the end of 2020. The additional 74 patients in Part A will receive the same treatment regimen and dosing schedule.

The expansion follows the encouraging interim data presented at SITC as announced on 10th November 2020 including an Overall Response Rate (ORR) of 39.4% in evaluable patients (n=36), Disease Control Rate of 66.7% and two complete responses (complete disappearance of all lesions) from 1st line NSCLC patients enrolled in Part A. In addition, efti plus pembrolizumab continues to be safe and well tolerated with no new safety signals reported so far.

Immutep CEO, Marc Voigt said: “We are excited to expand our collaboration trial with MSD, one of the world’s leading immuno-oncology companies. The interim results reported from 1st line NSCLC patients have been consistently encouraging and signal good efficacy, particularly for low PD-L1 expressing patients who do not typically respond to immune checkpoint therapy. Not only does this give us great confidence expanding the TACTI-002 trial, but it also validates our strategy to form and grow multiple collaborations with innovative large pharma companies, such as MSD, that are seeking to augment the efficacy of their existing approved products, like Keytruda.”

Immutep Commences Planning for New Phase II Clinical Trial in Head and Neck Cancer

Separately, Immutep has commenced planning for a new Phase II, randomised, controlled clinical study in approximately 160 1st line HNSCC patients. Patients will be 1:1 randomised to receive efti in combination with an anti-PD-1 treatment, or anti-PD-1 monotherapy. The trial is intended to take place across clinical sites in the United States, Australia and Europe.

Immutep CEO, Marc Voigt said: “Efti has shown very encouraging results in head and neck cancer in the 2nd line setting with PD-X naïve patients as demonstrated by the results reported at SITC. This has given us great confidence to explore it as a therapy in the commercially more relevant 1st line therapy setting and we have initated planning for a new randomized clinical study. We hope to share additional details in the near future. This advances our development program into later stage clinical development.”

About the TACT-002 Trial

TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). The study is evaluating the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 183 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

The trial is a Phase II, Simon’s two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in study centres across Australia, Europe, and the US.

Patients participate in one of the following:

  • Part A – First line Non-Small Cell Lung Cancer (NSCLC), PD-X naive
  • Part B – Second line NSCLC, PD-X refractory
  • Part C – Second line Head and Neck Squamous Cell Carcinoma (HNSCC), PD-X naive

TACTI-002 is an all comer study in terms of PD-L1 status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC. PD-L1 expression is typically reported in three groups for NSCLC: < 1%, 1-49% and ≥ 50% (Tumour Proportion Score or TPS) and in HNSCC: < 1%, 1-19% and ≥ 20% (Combined Positive Score or CPS). Patients with a high PD-L1 status are typically more responsive to anti-PD-1 therapy such as pembrolizumab, whereas those with low PD-L1 status are overall significantly less responsive. Pembrolizumab monotherapy is registered in the US and the EU for first line NSCLC patients with a TPS score ≥ 1% (US) and ≥ 50% (EU), reflecting 65% and 30% of all first line NSCLC patients, respectively. Pembrolizumab monotherapy is registered in the US (regardless of PD-L1 expression) and EU (≥ 50% TPS score) for second line HNSCC patients.

More information about the trial can be found on Immutep’s website or on ClinicalTrials.gov (Identifier: NCT03625323)

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; [email protected]

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]



Roman DBDR Tech Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants Commencing November 19, 2020

New York, New York, Nov. 18, 2020 (GLOBE NEWSWIRE) — Roman DBDR Tech Acquisition Corp. (the “Company”) announced today that, commencing November 19, 2020,  holders of the units sold in the Company’s initial public offering may elect to separately trade the shares of Class A common stock and warrants included in the units. Any units not separated will continue to trade on the Nasdaq Stock Market (the “Nasdaq”) under the symbol “DBDRU”, and the shares of Class A common stock and warrants will separately trade on the Nasdaq under the symbols “DBDR” and “DBDRW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, to separate the units into shares of Class A common stock and warrants.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on November 5, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from B. Riley Securities, Inc. at 1300 17th Street N., Suite 1400, Attn: Syndicate Prospectus Department, Arlington, Virginia 22209, by telephone at (800) 846-5050 or by email at [email protected].


About Roman DBDR Tech Acquisition Corp.

Roman DBDR Tech Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any stage of its corporate evolution or in any industry or sector, it intends to focus its search on companies in the technology, media and telecom (“TMT”) industries. The Company is led by its Co-Chief Executive Officers, Dr. Donald G. Basile and Dixon Doll, Jr.


Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

Dr. Don Basile
Co-CEO and Chairman
[email protected]
(650) 618-2524